NewsMV
LLY is in focus after Eli Lilly easily topped quarterly earnings estimates and raised its full-year 2026 revenue outlook, with Zepbound and Mounjaro sales cited as the demand catalyst.
The company now guides for 2026 revenue of $85 billion to $87 billion, against a prior range of $82 billion to $85 billion. The next confirmable event is the formal filing that will carry product-level revenue detail.
The guidance raise Both ends of Eli Lilly's 2026 revenue range moved higher after Zepbound and Mounjaro exceeded sales expectations in the quarter. The low end rose from $82 billion to $85 billion.
The high end moved from $85 billion to $87 billion, setting a new ceiling for the year. Lilly pointed directly to the two drugs as the reason for the raised guidance.
Keep reading